Current and Future Approaches to Immunotherapy
The History of Cell and Gene Therapy
Immunotherapies Used to Treat Cancer
Frequently Asked Questions About Cell and Gene Therapies
The Technology Behind Bone Marrow Cellular Processing: The PXP® System
Pioneering the Development of Automated Technologies for Cell-Based Therapeutics and Bioprocessing
For more than two decades ThermoGenesis Holdings, Inc. has developed and commercialized novel cell processing systems and devices providing global researchers, biomanufacturing organizations and clinicians with highly efficient cell processing devices which helped them to deliver better outcomes in various applications in the cell and gene therapy field.
Clinical BioBanking
With over 20 years of providing cord blood to banks hospitals, researchers and stem clinicians with systems designed to handle stem cells with the highest level of precision, safety, and confidence.
Point-of-Care Solutions
We develop products to obtain bone marrow concentrates easily, consistently, and reliably from bone marrow aspirates at the point-of-care with minimal red blood cell contamination.
Cellular Processing
The first step in the process is often the most important. That's why we have created closed-system novel and innovative technologies aimed at advancing cell therapies to the clinic.
Products for Cellular Processing and Storage
We offer closed automated solutions for manual steps in the cell manufacturing process. Our flexible automated modules provide performance gains in purifying mononuclear cells, washing contaminants from cell fractions, cell selection, and storage while significantly shortening processing times.
X-LAB® System
Rapid isolation of mononuclear cells in a closed system without the need of additional media or manual transfer steps makes the X-LAB System one of a kind. The X-LAB System can be customized to accommodate a range of blood products, input volumes and programmed to provide a specific final product without the need of highly skilled personnel provides great flexibility without compromising MNC recovery.
BioArchive® System
The BioArchive® System is the world’s leading system for preserving and protecting high value cells. It uses proven, computer-controlled technology and tracking software to provide the best protection for today’s valuable samples to meet tomorrow’s cell therapy needs. Fully automated, closed-system sample handling with robotic storage and retrieval ensures consistent temperature control and traceability.
PXP-1000™ System
Efficient processing and separation of cord blood through centrifugation in a fully automated system, the PXP-1000 System is designed to obtain the highest concentration of valuable stem cells and ensuring that they retain their viabilities. The PXP-1000 System accomplishes those tasks in a consistent final volume while reducing more contaminating red blood cells than other systems on the market, making a purer product.
3D Bag Set
The 3D Bag Set is uniquely designed to facilitate the transfer of buffy coat for storage and allows for addition of cryoprotectant in a closed sterile manner. The ease of use, traceability, durability, and safety that the 3D bag Set offers shall allow for long-term storage of the precious cells.
Recent News
ThermoGenesis Holdings to Present at the H.C. Wainwright 24th Annual Global Investment Conference
RANCHO CORDOVA, Calif., September 7, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September … Continued
ThermoGenesis Holdings Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update
Driven by Sales of the AXP, Total Revenues for the Quarter Rose 38% Compared to Prior Year Conference Call to be Held Today at 12:00 p.m. PT/3:00 p.m. ET RANCHO CORDOVA, Calif., August 11, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the … Continued
ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide a Corporate Strategic Update
Conference Call to be Held on August 11, 2022 RANCHO CORDOVA, Calif., August 9, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2022 … Continued
ThermoGenesis Holdings Announces Financial Results for the First Quarter Ended March 31, 2022 and Provides Corporate Update
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., May 19, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2022 … Continued
ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide a Corporate Strategic Update
Conference Call to be Held on May 19, 2022 RANCHO CORDOVA, Calif., May 18, 2022 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2022 … Continued